Qube Research & Technologies LTD 89bio, Inc. Transaction History

Qube Research & Technologies LTD

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$8.13 - $13.77 $3.14 Million - $5.32 Million	-386,224 Reduced 95.76%	17,100 $199,000
Q4 2023 Feb 13, 2024	BUY	$6.66 - $16.03 $2.69 Million - $6.47 Million	403,324 New	403,324 $4.51 Million
Q2 2023 Aug 14, 2023	BUY	$14.15 - $22.03 $45,605 - $71,002	3,223 Added 4.7%	71,754 $1.36 Million
Q1 2023 May 15, 2023	BUY	$10.48 - $16.94 $124,240 - $200,823	11,855 Added 20.92%	68,531 $1.04 Million
Q4 2022 Feb 14, 2023	BUY	$5.52 - $12.73 $220,209 - $507,837	39,893 Added 237.7%	56,676 $721,000
Q3 2022 Nov 14, 2022	BUY	$3.02 - $7.0 $50,684 - $117,481	16,783 New	16,783 $97,000

165

108M

73.6K

1.19M

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $532M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.